Salzman Investments (SI), based in Katzrin Israel, was founded in 2014 by Dr. Andrew Salzman. The Company was formed to leverage the respective expertise of Salzman Group in fundamental research, drug development, and commercialization. SI maintains a global network of strong personal relationships with clients, investors, strategic pharma, and scientists allowing us to serve as a forerunner and visionary in the field of biotechnology and investing. The combined influence and effort of our team’s experience and depth of knowledge have led to the identification and invention of a portfolio of innovative technologies based on Resolvins, a class of bioactive lipids that mediate resolution of inflammatory and auto-immune disease. The commercialization of such product opportunities is undertaken via private spin-off companies funded by external investors.


Quitsa Pharmaceuticals, Ltd. (Katzrin, Israel), founded in 2015 as a spin-out of Salzman Investments, is focused on the development of E-series Resolvins, a novel class of anti-inflammatory lipid mediators, for the treatment of refractory Crohn’s Disease and Atopic Dermatitis. The Company is poised to initiate Phase II clinical trials. Through the chemistry efforts of the Salzman Group, we have developed the first economically viable synthesis and stable formulation of Resolvin E1.


back to top